-
1
Moe S , et al.. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945–1953.
-
2
Sprague SM . Renal bone disease. Curr Opin Endocrinol Diabetes Obes 2010; 17:535–539.
-
3
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group . KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1–S130.
-
4
Palmer SC , et al.. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305:1119–1127.
-
5
Uhlig K . What should a guideline panel do when evidence is inconclusive? The case of treatments for CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2011; 58:872–875.
-
6
Uhlig K , et al.. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55:773–799.
-
7
National Kidney Foundation . K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl 3):S1–S201.
Highlights of the KDIGO Bone and Mineral Disorder Guidelines
Search for other papers by Menaka Sarav in
Current site
Google Scholar
PubMed
Search for other papers by Stuart M. Sprague in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory